Tensions in the Middle East shake Wall Street as healthcare stocks surge. Discover top gainers, Novo Nordisk's moves, and big pharma M&A updates.

aCDC COVID-19 Response Team, Centers for Disease Control and Prevention, Atlanta, GA, USA bEpidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA ...

The latest health news covers FDA's extended review of KalVista's drug, UroGen's new bladder cancer treatment approval, ...

AstraZeneca could spend up to $5.3 billion in a deal to develop oral medicines with CSPC Pharmaceutical. Elsewhere, Insmed ...

BioNTech announces CureVac acquisition for $1.25 billion in stock to strengthen cancer therapy pipeline and mRNA technology ...

BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy ...

BioNTech continued to grow its oncology business by agreeing to buy fellow German biotech CureVac for $1.25 billion in a deal that combines two of the world's leaders in mRNA treatments.

Plus: Oracle posts strong quarterly results boosted by the company's artificial-intelligence investments. Biotech company BioNTech acquires CureVac. Adobe raises its full-year outlook after posting ...

Three years after litigation started over technology used in an mRNA vaccine for COVID-19, Biontech SE is acquiring its ...

Health-care companies rose amid deal activity. BioNTech will acquire all shares of CureVac after the two sides reached an agreement in a deal valued around $1.25 billion.

Key developments in US health news include the release of new dietary guidelines, FDA approvals for bladder and lung cancer drugs, and significant policy shifts by U.S. Health Secretary Robert F.

The BioNTech SE acquisition of CureVac N.V. brings together complementary technologies, as both are developing mRNA ...